NK1-receptor antagonists for treating restless legs syndrome
OwnerHans-Michael Brecht, Birgit Junginventors
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of NK1-receptor antagonists for preparing a pharmaceutical composition for treating Restless Legs Syndrome (RLS) and methods for treating RLS using such compounds.
Claims8
A method for treating Restless Legs Syndrome (RLS) comprising administering a neurokinin 1 (NK1)-receptor antagonist.
A method for treating Restless Legs Syndrome (RLS) comprising administering a neurokinin 1 (NK1)-receptor antagonist, wherein the NK1-receptor antagonist is selected from the group consisting of BIIF 1149, NKP 608C, NKP 608A, CGP 60829, SR 140333 (Nolpitantium besilate/chloride), LY 303870 (Lanepitant), MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, YM-49244, YM-44778, ZM-274773, MEN-10930, S-19752, Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK-33A, 6b-I, CJ-11974, TAK-637, and GR 205171.
Dependencies are inferred from the claim text.